Comparison of clinical features of multiple myeloma with paraosseous and extraosseous plasmacytoma in the era of novel drugs: a systemic review and meta-analysis

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538–48. PubMed PMID: 25439696.
   PubMed Web of Science ®Google Scholar
• Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma. Curr Opin Oncol. 2020 Mar;32(2):170–175. PubMed PMID: 31895122.
   PubMed Web of Science ®Google Scholar
• Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014 Feb;99(2):360–364. PubMed PMID: 24038024; PubMed Central PMCID: PMCPMC3912968.
   PubMed Web of Science ®Google Scholar
• Batsukh K, Lee SE, Min GJ, et al. Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma. Immune Netw. 2017 Aug;17(4):250–260. PubMed PMID: 28860954; PubMed Central PMCID: PMCPMC5577302.
   PubMed Web of Science ®Google Scholar
• Oriol A. Multiple myeloma with extramedullary disease. Adv Ther. 2011 Nov;28(Suppl 7):1–6. PubMed PMID: 22105527.
   PubMedGoogle Scholar
• Dahl IM, Rasmussen T, Kauric G, et al. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol. 2002 Feb;116(2):273–277. PubMed PMID: 11841427.
   PubMed Web of Science ®Google Scholar
• Chang H, Bartlett ES, Patterson B, et al. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol. 2005 May;129(4):539–541. PubMed PMID: 15877737.
   PubMed Web of Science ®Google Scholar
• Hargreaves DC, Hyman PL, Lu TT, et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J Exp Med. 2001 Jul 2;194(1):45–56. PubMed PMID: 11435471; PubMed Central PMCID: PMCPMC2193440.
   PubMed Web of Science ®Google Scholar
• Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015 Jul 28;12(4):622–635. PubMed PMID: 26190113; PubMed Central PMCID: PMCPMC4961259.
   PubMed Web of Science ®Google Scholar
• de Haart SJ, Willems SM, Mutis T, et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J. 2016 May20;6(5):e426. PubMed PMID: 27206246; PubMed Central PMCID: PMCPMC4916304.
   PubMedGoogle Scholar
• Beksac M, Seval GC, Kanellias N, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020 Jan;105(1):201–208. PubMed PMID: 31278209; PubMed Central PMCID: PMCPMC6939516.
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998 Dec 30;17(24):2815–2834. PubMed PMID: 9921604.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015 Jan;263(1):160–172. PubMed PMID: 25510276.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013 Jun;54(6):1135–1141. PubMed PMID: 23210572.
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010 Feb;21(2):325–330. PubMed PMID: 19633044.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012 Nov;97(11):1761–1767. PubMed PMID: 22689675; PubMed Central PMCID: PMCPMC3487453.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Foureau DM, Atrash S, et al. Extramedullary multiple myeloma. Leukemia. 2020 Jan;34(1):1–20. PubMed PMID: 31776467.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Kim K, Lee JW, et al. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma. Eur J Haematol. 2014 Nov;93(5):414–421. PubMed PMID: 24813053.
   PubMed Web of Science ®Google Scholar
• Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994 Nov;12(11):2398–2404. PubMed PMID: 7964956.
   PubMed Web of Science ®Google Scholar
• Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 Jun;91(6):575–580. PubMed PMID: 26955792; PubMed Central PMCID: PMCPMC5502095.
   PubMed Web of Science ®Google Scholar
• Richardson AS PG, Cannell P, Harrison SJ, et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). Blood. 2011;118(21): 302. DOI: https://doi.org/10.1182/blood.V118.21.302.302.
   Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica. 2018 May;103(5):890–897. PubMed PMID: 29419433; PubMed Central PMCID: PMCPMC5927971.
   PubMed Web of Science ®Google Scholar
• Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004 Jul;89(7): 832–836. PubMed PMID: 15257935.
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011 Oct 1;29(28):3805–3812. PubMed PMID: 21900099.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Sevcikova T, Zihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2021 Jul 10;36(1):288–291. PubMed PMID: 34247197.
   PubMed Web of Science ®Google Scholar
• Daratumumab Combined With Bortezomib, Cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease (EMN19). 2019 [cited March 10 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT04166565
   Google Scholar